{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:13:48Z","timestamp":1791843228033,"version":"4.3.4"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis C virus (HCV) infection has been associated with osteoporosis and fragility fracture, which may be mediated by increased systemic inflammation, especially in HIV-HCV co-infection. Treatment with direct-acting antivirals (DAA) eradicates HCV and decreases inflammation, but the impact on bone parameters has not been studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recruited individuals with HCV infection with and without HIV co-infection who initiated DAA, and a demographically matched reference group without HIV or HCV, on whom dual-energy X-ray absorptiometry (DXA) scans were performed at baseline. All participants with HCV who displayed sustained virologic response were included and underwent a follow up visit with DXA between 52 and 134 weeks after baseline to measure bone mineral density at the lumbar spine (LS), femoral neck (FN), and total hip (TH), as well as the trabecular bone score (TBS), a bone quality measure. Bone turnover markers (BTM) and inflammatory biomarkers were also measured at baseline and the follow-up visit. We compared the change in inflammatory biomarkers and bone outcomes over time between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The group with HCV (41 mono-infected, 18 people with HIV\/HCV co-infection) had a median age of 54 years; 61% were male and 76% were African American. Population characteristics were similar in the reference group (n=53). At baseline, soluble receptor for TNF\u03b1 1 and 2 (sTNFR-1\/sTNFR-2) and sCD163 concentrations, but not interleukin-6, were higher in participants with HCV infection compared to the reference group. After a median follow-up period of 60 weeks, HCV cure was associated with decreases in sTNFR1, sTNFR2 and sCD163 concentrations. However, we observed no statistically significant changes in BMD, TBS or BTM after HCV treatment compared to the reference population. Among those with HCV, participants with HIV co-infection showed a significant increase in the bone formation marker P1NP (p&amp;lt;0.007) and trends toward greater increases in LS and TH BMD (p&amp;lt;0.08 for both) after HCV cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HCV cure using DAA was associated with a decrease in systemic inflammation without changes in bone parameters. The significant increase in bone formation markers observed in HIV\/HCV co-infected individuals suggests potential bone recovery in this high-risk group, warranting investigation in larger long-term studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1626875","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:28:58Z","timestamp":1764311338000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of HCV cure on systemic inflammation and bone density, quality, and turnover"],"prefix":"10.3389","volume":"16","author":[{"given":"Christina K.","family":"Psomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Lellouche-Slama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Langan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall F.","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Pena-Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Khati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison G.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad411","article-title":"Estimated prevalence and awareness of hepatitis C virus infection among US adults: national health and nutrition examination survey, January 2017-March 2020","volume":"77","author":"Lewis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B2","unstructured":"Hepatitis C\n          \n          \n          \n          2023"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","first-page":"31","article-title":"Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma","volume":"51","author":"Leone","year":"2005","journal-title":"Minerva Gastroenterol Dietol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","article-title":"Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C","volume":"42","author":"Cacoub","year":"1999","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2049936115585942","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"Cacoub","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316234","article-title":"Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis","volume":"67","author":"Cacoub","year":"2018","journal-title":"Gut"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100658","DOI":"10.1016\/j.lana.2023.100658","article-title":"Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada","volume":"29","author":"Jeong","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/v13112249","article-title":"A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy","volume":"13","author":"Mazzaro","year":"2021","journal-title":"Viruses"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-012-9653-y","article-title":"Association between chronic hepatitis C virus infection and bone mineral density","volume":"91","author":"Lin","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002086","article-title":"Relation between hepatitis C virus exposure and risk of osteoporosis: A nationwide population-based study","volume":"94","author":"Chen","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_452_16","article-title":"Hepatitis C virus infection and risk of osteoporosis: A meta-analysis","volume":"23","author":"Wijarnpreecha","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jhep.2014.03.007","article-title":"Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study","volume":"61","author":"Hansen","year":"2014","journal-title":"J Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3507-6","article-title":"Bone mineral density, bone turnover, and systemic inflammation in non-cirrhotics with chronic hepatitis C","volume":"60","author":"Lai","year":"2015","journal-title":"Dig Dis Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.01.035","article-title":"Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV\/HCV co-infection","volume":"55","author":"El-Maouche","year":"2011","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4354-z","article-title":"Bone density and microarchitecture in hepatitis C and HIV-coinfected postmenopausal minority women","volume":"29","author":"TY","year":"2018","journal-title":"Osteoporos Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2020.06.020","article-title":"HCV co-infection among people living with HIV Is associated with Higher fracture risk","volume":"13","author":"Pramukti","year":"2020","journal-title":"J Infect Public Health"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000259","article-title":"Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture","volume":"11","author":"Bedimo","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25866","article-title":"Risk of hip fracture associated with hepatitis C virus infection and hepatitis C\/human immunodeficiency virus coinfection","volume":"56","author":"Lo Re","year":"2012","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000363","article-title":"Osteoporosis and fractures in HIV\/hepatitis C virus coinfection: a systematic review and meta-analysis","volume":"28","author":"Dong","year":"2014","journal-title":"AIDS"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1011","article-title":"The differential effects of human immunodeficiency virus and hepatitis C virus on bone microarchitecture and fracture risk","volume":"66","author":"Bedimo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv147","article-title":"Structural bone deficits in HIV\/HCV-coinfected, HCV-monoinfected, and HIV-monoinfected women","volume":"212","author":"Lo Re","year":"2015","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3390\/jcm11092382","article-title":"Secondary osteoporosis and metabolic bone diseases","volume":"11","author":"Sobh","year":"2022","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179400","article-title":"Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon","volume":"12","author":"Mascia","year":"2017","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jvh.13204","article-title":"Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C","volume":"27","author":"Laursen","year":"2020","journal-title":"J Viral Hepat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0204","article-title":"Effects of pegylated interferon\/ribavirin on bone turnover markers in HIV\/hepatitis C virus-coinfected patients","volume":"32","author":"Bedimo","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01038.x","article-title":"Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy","volume":"15","author":"Hofmann","year":"2008","journal-title":"J Viral Hepat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-017-0013-x","article-title":"Pegylated interferon alpha\/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection","volume":"13","author":"Megahed","year":"2017","journal-title":"World J Pediatr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1396","article-title":"Effects of hepatitis C virus (HCV) eradication on bone mineral density in human immunodeficiency virus\/HCV-coinfected patients","volume":"73","author":"Carrero","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2006.01.004","article-title":"Interferon-alpha improves bone resorption and osteopenia in patients with chronic hepatitis C","volume":"34","author":"Nishida","year":"2006","journal-title":"Hepatol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00337.x","article-title":"Interplay between interferon and other cytokine systems in bone metabolism","volume":"208","author":"Takayanagi","year":"2005","journal-title":"Immunol Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11010-006-9293-5","article-title":"Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE\/RANKL","volume":"296","author":"Lee","year":"2007","journal-title":"Mol Cell Biochem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.7.821","article-title":"Two brief alcohol-screening tests From the Alcohol Use Disorders Identification Test (AUDIT): validation in a female Veterans Affairs patient population","volume":"163","author":"Bradley","year":"2003","journal-title":"Arch Intern Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1249\/01.MSS.0000078924.61453.FB","article-title":"International physical activity questionnaire: 12-country reliability and validity","volume":"35","author":"Craig","year":"2003","journal-title":"Med Sci Sports Exerc"},{"key":"B37","unstructured":""},{"key":"B38","unstructured":""},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2012.05.001","article-title":"Three-dimensional (3D) microarchitecture correlations with 2D projection image gray-level variations assessed by trabecular bone score using high-resolution computed tomographic acquisitions: effects of resolution and noise","volume":"16","author":"Winzenrieth","year":"2013","journal-title":"J Clin Densitom"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3996","article-title":"T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial","volume":"35","author":"Cosman","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106339200","article-title":"Expression of the osteoblast differentiation factor RUNX2 (Cbfa1\/AML3\/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha","volume":"277","author":"Gilbert","year":"2002","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M103642200","article-title":"Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK","volume":"276","author":"Lee","year":"2001","journal-title":"J Biol Chem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"ofad623","DOI":"10.1093\/ofid\/ofad623","article-title":"Changes in inflammatory cytokines after chronic hepatitis C treatment among people living with HIV","volume":"11","author":"Karimi-Sari","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167934","article-title":"DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment","volume":"11","author":"Villani","year":"2016","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3390\/pathogens10111488","article-title":"Short- and long-term immunological responses in chronic HCV\/HIV co-infected compared to HCV mono-infected patients after DAA therapy","volume":"10","author":"Farcomeni","year":"2021","journal-title":"Pathogens"},{"key":"B47","doi-asserted-by":"publisher","first-page":"11936","DOI":"10.3390\/ijms231911936","article-title":"Longitudinal assessment of multiple immunological and inflammatory parameters during successful DAA therapy in HCV monoinfected and HIV\/HCV coinfected subjects","volume":"23","author":"Zuccala","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.723196","article-title":"HCV cure with direct-acting antivirals improves liver and immunological markers in HIV\/HCV-coinfected patients","volume":"12","author":"BroChado-Kith","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"ofab079","DOI":"10.1093\/ofid\/ofab079","article-title":"T-cell activation is correlated with monocyte activation in HCV\/HIV coinfection and declines during HCV direct-acting antiviral therapy","volume":"8","author":"Auma","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa254","article-title":"Hepatitis C virus (HCV) direct-acting antiviral therapy in persons with human immunodeficiency virus-HCV genotype 1 coinfection resulting in high rate of sustained virologic response and variable in normalization of soluble markers of immune activation","volume":"222","author":"Anthony","year":"2020","journal-title":"J Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1120083","article-title":"Seropositive for hepatitis B and C viruses is associated with the risk of decreased bone mineral density in adults: An analysis of studies from the NHANES database","volume":"10","author":"Tao","year":"2023","journal-title":"Front Med (Lausanne)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:29:01Z","timestamp":1764311341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2025.1626875"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1626875","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1626875"}}